Background Ivabradine specifically inhibits the I f current in the sinoatrial node to lower heart
rate, without affecting other aspects of cardiac function. We aimed to test whether lowering …

Background The BEAUTIFUL study assessed the morbidity and mortality benefits of the
heart rate-lowering agent ivabradine. The placebo arm of the BEAUTIFUL trial was a large …

Background Approximately half of people with heart failure have chronic kidney disease
(CKD). Pharmacological interventions for heart failure in people with CKD have the potential …

Side effects account for most of the instances of failure of candidate drugs at late stages of
development. These development failures contribute to the exorbitant cost of bringing new …

Chronic heart failure (CHF) represents a major cause of hospitalization and death. Recent
evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2) …

Heart rate is an important contributor in the pathophysiology of both coronary artery disease
(CAD) and heart failure (HF). Ivabradine is an anti-anginal and anti-ischaemic agent, which …

Heart failure with preserved ejection fraction (HFpEF) has become an emerging concern.
The protective effect of bradycardia in patients with reduced ejection fraction using beta …

The aim of this study was to investigate the effect of chronic heart rate (HR) reduction with
the hyperpolarization-activated current inhibitor ivabradine on the global phenotype of left …

This article explores the relativistic principle that there is no privileged scale of causality in
biology to clarify the relationships between genomes and phenotypes. The idea that genetic …

Purpose Ivabradine is a novel I f-channel antagonist that controls heart rate and may be
helpful in treating patients with left ventricular dysfunction (LVD) who are unable to tolerate β …